Relationship between daunorubicin concentration and apoptosis induction in leukemic cells-Reference-Cited by-同舟云学术

Relationship between daunorubicin concentration and apoptosis induction in leukemic cells

Published:2004-03 Issue:6 Volume:67 Page:1047-1056
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Masquelier Michèle,Zhou Qi Feng,Gruber Astrid,Vitols Sigurd

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference28 articles.

1. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission;Stein;Leukemia,2000

2. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin;Todeschini;Leukemia,1998

3. Acute myeloid leukemia in adults;Cripe;Curr. Treat. Options Oncol.,2000

4. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61–65 years;Schaich;Haematologica,2002

5. Apoptosis and resistance to daunorubicin in human leukemic cells;Efferth;Leukemia,1997

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SpinTip: A Simple, Robust, and Versatile Preanalytical Method for Microscale Suspension Cell Proteomics;Journal of Proteome Research;2022-10-14

2. Intrinsic and extrinsic apoptosis responses in leukaemia cells following daunorubicin treatment;BMC Cancer;2021-04-21

3. Synthesis and biological activity of siRNA and Etoposide with magnetic nanoparticles on drug resistance model MCF-7 Cells: Molecular docking study with MRP1 enzyme;NANOMED J;2021

4. Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors;Cancers;2020-06-16

5. Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin;Bioscience Reports;2019-09